🚀 VC round data is live in beta, check it out!
Agenus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Agenus and similar public comparables like Naturland Holding, Oncolytics Biotech, Precision BioSciences, XSpray Pharma and more.
Agenus Overview
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Founded
1999
HQ
Employees
316
Website
Sectors
Financials (LTM)
EV
$158M
Agenus Financials
Agenus reported last 12-month revenue of $127M.
In the same LTM period, Agenus generated $6M in net income.
Revenue (LTM)
Agenus P&L
In the most recent fiscal year, Agenus reported revenue of $103M and EBITDA of ($101M).
Agenus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $127M | XXX | $103M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($53M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (51%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($101M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (98%) | XXX | XXX | XXX |
| EBIT Margin | (4%) | XXX | (120%) | XXX | XXX | XXX |
| Net Profit | $6M | XXX | ($227M) | XXX | XXX | XXX |
| Net Margin | 5% | XXX | (220%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Agenus Stock Performance
Agenus has current market cap of $116M, and enterprise value of $158M.
Market Cap Evolution
Agenus' stock price is $3.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $116M | 0.0% | XXX | XXX | XXX | $-6.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAgenus Valuation Multiples
Agenus trades at 1.2x EV/Revenue multiple, and (1.6x) EV/EBITDA.
EV / Revenue (LTM)
Agenus Financial Valuation Multiples
As of March 18, 2026, Agenus has market cap of $116M and EV of $158M.
Equity research analysts estimate Agenus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Agenus has a P/E ratio of 20.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $116M | XXX | $116M | XXX | XXX | XXX |
| EV (current) | $158M | XXX | $158M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/EBIT | (28.4x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (3.0x) | XXX | XXX | XXX |
| P/E | 20.2x | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Agenus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Agenus Margins & Growth Rates
Agenus' revenue in the last 12 month grew by 33%.
Agenus' revenue per employee in the last FY averaged $0.4M.
Agenus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (98%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (31%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 70% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 74% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 70% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Agenus Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Naturland Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncolytics Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Precision BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XSpray Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Black Diamond Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Agenus M&A Activity
Agenus acquired XXX companies to date.
Last acquisition by Agenus was on XXXXXXXX, XXXXX. Agenus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Agenus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAgenus Investment Activity
Agenus invested in XXX companies to date.
Agenus made its latest investment on XXXXXXXX, XXXXX. Agenus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Agenus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Agenus
| When was Agenus founded? | Agenus was founded in 1999. |
| Where is Agenus headquartered? | Agenus is headquartered in United States. |
| How many employees does Agenus have? | As of today, Agenus has over 316 employees. |
| Who is the CEO of Agenus? | Agenus' CEO is Garo H. Armen. |
| Is Agenus publicly listed? | Yes, Agenus is a public company listed on Nasdaq. |
| What is the stock symbol of Agenus? | Agenus trades under AGEN ticker. |
| When did Agenus go public? | Agenus went public in 2000. |
| Who are competitors of Agenus? | Agenus main competitors are Naturland Holding, Oncolytics Biotech, Precision BioSciences, XSpray Pharma. |
| What is the current market cap of Agenus? | Agenus' current market cap is $116M. |
| What is the current revenue of Agenus? | Agenus' last 12 months revenue is $127M. |
| What is the current revenue growth of Agenus? | Agenus revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Agenus? | Current revenue multiple of Agenus is 1.2x. |
| Is Agenus profitable? | Yes, Agenus is net-income-positive (as of the last 12 months). |
| What is the current net income of Agenus? | Agenus' last 12 months net income is $6M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.